MONTVALE, N.J., Nov. 12 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp.
(Nasdaq: MEMY) today announced the appointment of Paul Blake to the Company's
Board of Directors effective November 9, 2007. Dr. Blake has over 27 years of
clinical development experience. He currently serves as the Senior Vice
President and Chief Medical Officer of AEterna Zentaris Inc., a
bio-pharmaceutical company. Previously, Dr. Blake was Senior Vice President,
Clinical Research and Development for Avigenics Inc. From 2001 to 2006, Dr.
Blake was with Cephalon, Inc. in the clinical research and regulatory affairs
group, most recently as Executive Vice President, Worldwide Medical and
Regulatory Operations. He has also served as Chief Medical Officer for MDS
Proteomics, Inc. and as Medical Director for SmithKline Beecham
Pharmaceuticals, where he was responsible for its worldwide clinical research
and development operations.
"We are delighted to welcome Paul to the Board of Directors of Memory
Pharmaceuticals," said Jonathan Fleming, Co-founder of Memory Pharmaceuticals
and Chairman of the Company's Board of Directors. "Paul brings to Memory's
Board a wealth of experience leading the clinical development of early and
late-stage drug candidates, across a range of therapeutic areas. We believe his
expertise will be of tremendous value as our pipeline matures and our compounds
advance through the clinical trial process."
"I am excited to be joining the Memory Pharmaceuticals Board," stated Dr.
Blake. "The Company has a robust and diverse portfolio of compounds in
development for the treatment of debilitating central nervous system disorders,
and I look forward to working with the Company and, in particular, the clinical
development team as they move current programs into new indications and later
stage trials and take new programs into the clinic."
Dr. Blake received his M.B. and B.S. at London University and is a fellow of
the American College of Clinical Pharmacology and the Royal College of
Physicians in the United Kingdom.
About the Company
Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on
developing innovative drugs for the treatment of debilitating CNS disorders
such as Alzheimer's disease, schizophrenia and depression. For additional
information, please visit our website at http://www.memorypharma.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 that are subject to risks
and uncertainties. All statements, other than statements of historical facts,
regarding management's expectations, beliefs, goals, plans or Memory
Pharmaceuticals' prospects, future financial position, future revenues and
projected costs should be considered forward-looking. Readers are cautioned
that actual results may differ materially from projections or estimates due to
a variety of important factors, including the risks and uncertainties
associated with: obtaining additional financing to support Memory
Pharmaceuticals' R&D and clinical activities and operations; the outcome of
clinical trials of Memory Pharmaceuticals' drug candidates and whether they
demonstrate these candidates' safety and effectiveness; obtaining regulatory
approvals to conduct clinical trials and to commercialize Memory
Pharmaceuticals' drug candidates; Memory Pharmaceuticals' ability to enter into
and maintain collaborations with third parties for its drug development
programs; Memory Pharmaceuticals' dependence on its collaborations and its
license relationship with Bayer; achieving milestones under Memory
Pharmaceuticals' collaborations; Memory Pharmaceuticals' dependence on
preclinical and clinical investigators, preclinical and clinical research
organizations, manufacturers and consultants; and protecting the intellectual
property developed by or licensed to Memory Pharmaceuticals. These and other
risks are described in greater detail in Memory Pharmaceuticals' filings with
the Securities and Exchange Commission. Memory Pharmaceuticals may not actually
achieve the goals or plans described in its forward-looking statements, and
investors should not place undue reliance on these statements. Memory
Pharmaceuticals disclaims any intent or obligation to update any
forward-looking statements as a result of developments occurring after the date
of this press release.
SOURCE Memory Pharmaceuticals Corp.
-0- 11/12/2007
/CONTACT: Jzaneen Lalani, General Counsel of Memory Pharmaceuticals Corp.,
+1-201-802-7249, or Laura Perry of Stern Investor Relations, Inc.,
+1-212-362-1200, for Memory Pharmaceuticals Corp./
/Web site: http://www.memorypharma.com /
(MEMY)
CO: Memory Pharmaceuticals Corp.
ST: New Jersey
IN: BIO HEA MTC
SU: PER
CH-MC
-- NYM089 --
8640 11/12/2007 16:10 EST http://www.prnewswire.com
